Literature DB >> 3486827

Suppressive and augmentative effects of recombinant human interleukin-2 upon delayed type of hypersensitivity in the mouse.

M Harada, K Mori, H Nishimoto.   

Abstract

The in vivo action of recombinant human interleukin-2 (IL-2) was investigated against the delayed type of footpad swelling to sheep red blood cells (SRBC) in B6D2F1 mice. A single intravenous injection of 1 X 10(5) of SRBC induced transient cell-mediated immunity for delayed type of hypersensitivity (DTH) which peaked four days after the immunization and diminished rapidly thereafter. IL-2 exerted both suppressive and augmentative effects, depending on the timing of its administration in relation to the immunization. Daily intraperitoneal injections of as much as 5 X 10(4) Jurkat units of IL-2 from day 0 through day 3 caused marked suppression of DTH elicited on day 4. On the other hand, three or four consecutive injections of IL-2 from day 4 or day 3 through day 6 produced potent DTH on day 7, when DTH was faint, if there was any, without IL-2 administration. Potentiation of DTH was also observed when three injections of IL-2 were given from day 7 through day 9 and the antigen was challenged on day 10. These results suggest that IL-2 acts as an immunomodulator against cell-mediated immunity to SRBC in the mouse.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3486827     DOI: 10.1007/BF00915998

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  11 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

2.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

Review 3.  T-cell growth factor and the culture of cloned functional T cells.

Authors:  K A Smith; F W Ruscetti
Journal:  Adv Immunol       Date:  1981       Impact factor: 3.543

Review 4.  T-cell growth factor.

Authors:  K A Smith
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

5.  Suppressed antibody responses to sheep erythrocytes in mice with chronic Trypanosoma cruzi infections are restored with interleukin 2.

Authors:  S G Reed; J A Inverso; S B Roters
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

6.  Interleukin-2 allows in vivo induction of anti-erythrocyte autoantibody production in nude mice associated with the injection of rat erythrocytes.

Authors:  J Reimann; T Diamantstein
Journal:  Clin Exp Immunol       Date:  1981-03       Impact factor: 4.330

7.  Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

Authors:  M A Cheever; P D Greenberg; A Fefer; S Gillis
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

8.  T cell factor (interleukin 2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice.

Authors:  H Stötter; E Rüde; H Wagner
Journal:  Eur J Immunol       Date:  1980-09       Impact factor: 5.532

9.  Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report.

Authors:  G Pizza; G Severini; D Menniti; C De Vinci; F Corrado
Journal:  Int J Cancer       Date:  1984-09-15       Impact factor: 7.396

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.